Traws Pharma, Inc.

TRAWSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1130598

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	—	$11.4M	$7.3M	$16.9M	$15.5M
Operating Expenses	$20.5M	$19.9M	$16.7M	$25.2M	$23.9M
Operating Income (Loss)	-$20.3M	-$19.6M	-$16.5M	-$25.0M	-$21.7M
Interest Expense	—	—	—	—	—
Other Nonoperating Income (Expense)	$1.4M	$663.0K	$12.0K	$48.0K	$143.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$18.9M	-$19.0M	-$16.2M	-$25.2M	—
Income Tax Expense (Benefit)	—	—	—	$4.0K	$10.0K
Net Income (Loss) Attributable to Parent	-$18.9M	-$19.0M	-$16.2M	-$25.2M	-$21.5M
Earnings Per Share, Basic	-$22.57	-$0.91	-$0.96	-$2.17	—
Earnings Per Share, Diluted	-$22.57	-$0.91	-$0.96	-$2.17	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$22.7M	$39.4M	$55.5M	$20.0M	$23.7M
Assets, Current	$22.7M	$39.3M	$55.4M	$19.8M	$23.5M
Cash and Cash Equivalents, at Carrying Value	—	$20.6M	$38.5M	—	—
Liabilities	$12.0M	$11.1M	$9.4M	$13.8M	$12.1M
Liabilities, Current	$9.2M	$8.0M	$6.1M	$10.0M	$8.3M
Accounts Payable, Current	$5.6M	$3.9M	$2.8M	$4.8M	$4.3M
Stockholders' Equity Attributable to Parent	—	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$17.9M	-$16.3M	-$19.5M	-$23.1M	-$20.8M
Net Cash Provided by (Used in) Investing Activities	-$14.0K	-$14.0K	—	-$15.0K	-$55.0K
Net Cash Provided by (Used in) Financing Activities	$34.0M	—	$55.6M	$19.4M	$26.6M
Payments to Acquire Property, Plant, and Equipment	$14.0K	$14.0K	—	$15.0K	$55.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)